当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Rare Tumors in Kids May Respond to Tazemetostat
Cancer Discovery ( IF 29.7 ) Pub Date : 2018-01-01 , DOI: 10.1158/2159-8290.cd-nb2017-152
American Association for Cancer Research

In a phase I trial of the EZH2 inhibitor tazemetostat, children with INI1-deficient tumors—including relapsed or refractory malignant rhabdoid tumors, atypical teratoid rhabdoid tumors, epithelioid sarcomas, and poorly differentiated chordomas—responded well to treatment, with some experiencing durable responses.



中文翻译:

孩子中的罕见肿瘤可能对Tazemetostat有所反应

在EZH2抑制剂tazemetostat的I期试验中,患有INI1缺陷的儿童-包括复发或难治的恶性横纹肌瘤,非典型性叔状横纹肌瘤,上皮样肉瘤和分化差的脊索瘤-对治疗的反应良好,有些经历了持久的反应。

更新日期:2018-01-08
down
wechat
bug